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Intravenous (i.v.) temsirolimus, a novel inhibitor of mammalian target of rapamycin, is approved for the treatment of advanced renal
cell carcinoma and is being studied in patients with mantle cell lymphoma. Because temsirolimus and its primary metabolite, sirolimus,
are metabolised by the cytochrome P450 3A4 pathway (CYP3A4), the potential exists for pharmacokinetic (PK) drug interactions
with the numerous agents that modulate CYP3A4 isozyme activity. We investigated the effects of ketoconazole, a potent CYP3A4
inhibitor, on the PK profile of i.v. temsirolimus in healthy adults. Coadministration of 400mg oral ketoconazole with 5mg i.v.
temsirolimus had no significant effect on temsirolimus maximum concentration (Cmax) or area under the concentration curve (AUC).
However, mean AUC increased 3.1-fold and AUCsum (sum of temsirolimus plus sirolimus AUCs) increased 2.3-fold compared with
temsirolimus alone. A single 5-mg dose of temsirolimus with ketoconazole was well tolerated, and there were no unexpected safety
results. Therefore, in cancer patients receiving 25mg i.v. temsirolimus, concomitant treatment with agents that have strong CYP3A4
inhibition potential should be avoided. If a concomitant strong CYP3A4 inhibitor is necessary, a temsirolimus dose reduction to
12.5mg weekly should be considered.
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Temsirolimus, a novel inhibitor of the mammalian target of
rapamycin (mTOR), improves overall survival and progression-
free survival in patients with advanced renal cell carcinoma (RCC)
compared with interferon (Hudes et al, 2007). Rash, peripheral
oedema, hyperglycaemia, and hypertriglyceridaemia were more
common in advanced RCC patients receiving temsirolimus,
whereas asthaenia occurred more often in patients receiving
interferon. In vitro, the activity of temsirolimus is facilitated by its
binding to the cytosolic FK506 binding protein-12, which in turn
binds to mTOR and inhibits its kinase activity (Skotnicki et al,
2001). Mammalian target of rapamycin is a central regulator of
various signal-transduction pathways, controlling synthesis of
proteins that are needed for cell proliferation, growth, survival,
and response to hypoxic stress (Schmelzle and Hall, 2000; Hudson
et al, 2002; Fingar et al, 2004). Inhibition of mTOR by
temsirolimus as a novel mechanistic strategy for the treatment of
other advanced malignancies, including mantle cell lymphoma, is
actively being studied in several clinical trials.
The principal metabolite of intravenous (i.v.) temsirolimus in
humans is sirolimus, which also displays mTOR inhibitory activity.
Clinically relevant pharmacokinetic (PK) exposure to i.v. temsiro-
limus is considered to be a composite of both temsirolimus and
sirolimus. Following administration of a single 25-mg dose of
temsirolimus in patients with RCC, temsirolimus mean maximum
concentration (Cmax) in whole blood was 595ngml
 1 (coefficient
of variation (CV)¼17%), and mean area under the curve (AUC)
was 1580nghml
 1 (s.d., CV¼17%) (Atkins et al, 2004). Sirolimus
appears rapidly and exhibits Cmax values 10–20% of temsirolimus
Cmax values (Atkins et al, 2004). However, owing in part to the
longer half-life of sirolimus, the sirolimus/temsirolimus AUCratio
indicates a 2.8-fold higher exposure to sirolimus relative to
temsirolimus over the course of treatment. Temsirolimus and
sirolimus are both cleared by the liver and are extensively excreted
in the faeces (Torisel, 2007). Because only small amounts are
excreted in urine, dispositions in RCC patients with nephrectomy
or renal impairment are not expected to differ substantially.
Temsirolimus and sirolimus are metabolised by cytochrome
P450 3A4 (CYP3A4) (Zimmerman, 2004; Cai et al, 2007); this
enzyme is responsible for the formation of five temsirolimus
metabolites (Torisel, 2007). Because CYP3A4 is the most abundant
CYP isozyme in humans and the pathway responsible for
metabolism of numerous xenobiotics (Shimada et al, 1994; Li
et al, 1995; Dresser et al, 2000), the potential for drug interaction
exists. Using in vitro liver microsome systems, ketoconazole, a
potent inhibitor of CYP3A4, decreased the formation of temsiro-
limus metabolites to 10–20% of control levels (IC50o2mM) (Cai
et al, 2007). Ketoconazole also inhibited the metabolism of
sirolimus (Ki¼2mM). Orally administered sirolimus exhibits a
substantial PK drug interaction with ketaconazole, resulting in
increased whole blood exposure to sirolimus (Zimmerman, 2004).
Oral structural analogues of sirolimus (tacrolimus and everolimus)
are also CYP3A4 substrates and exhibit strong drug interactions
with ketoconazole (Kovarik et al, 2005, 2006; El-Dahshan et al,
2006).
This drug interaction study was conducted in healthy adults to
assess the PK profile of a single i.v. dose of temsirolimus when
coadministered with multiple oral doses of the potent CYP3A4
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sinhibitor ketoconazole Because of the potential for increased
exposure when given with ketoconazole, a 5-mg dose of i.v.
temsirolimus was chosen to mitigate safety concerns of using the
25-mg clinical RCC dose in healthy subjects. The lower dose is also
a more sensitive indicator of PK drug interaction potential.
MATERIALS AND METHODS
Subjects
Men and women aged 18–45 years, inclusive, with a body mass
index between 18 and 30kgm
 2 and body weight of 50kg or more
were eligible for participation in this trial. Women were required
to be of non-childbearing potential due to hysterectomy and/or
oophorectomy or in menopause for more than 1 year, with an
oestradiol concentration of 20pgml
 1 or less and a follicle-
stimulating hormone level of at least 40mIUml
 1. They also were
required to have a negative serum pregnancy test within 48h of the
first temsirolimus administration (study day 1). Subjects with
significant cardiovascular, hepatic, renal, respiratory, endocrine,
immunologic, dermatologic, haematologic, neurologic, or psychia-
tric disease or a surgical or medical condition that could interfere
with the absorption, distribution, metabolism, or excretion of the
study medications were not enrolled. Those with positive HIV
antibodies, hepatitis B surface antigen, or hepatitis C virus
antibodies were also excluded. A normal physical exam, vital
signs, 12-lead electrocardiogram (ECG), and clinical laboratory
tests were required for inclusion in the study. Subjects with an
acute illness within 7 days of study day 1 were excluded. A history
of smoking fewer than 10 cigarettes per day and the ability to
refrain from smoking during the in-patient portion of the trial
were required for participation in the study. Subjects were
excluded if they had a history of drug or alcohol abuse (daily
consumption of more than 24 ounces of beer, 3 ounces of 80-proof
alcohol, or 12 ounces of wine) within 1 year of study day 1, and a
negative urine drug screen was required. Those with hypersensi-
tivity to temsirolimus or sirolimus, ketoconazole, or diphenhy-
dramine were also excluded. Use of investigational or prescription
drugs within 30 days of study day 1 or use of caffeine-containing
products, grapefruit, grapefruit-containing products, or alcoholic
beverages within 48h of study day 1 was not allowed. Subjects
could not take over-the-counter medications or herbal supple-
ments within 14 days of study day 1. All participants gave written
informed consent before the trial.
Study design
In this open-label, non-randomised, single-centre, two-period,
sequential study, subjects received temsirolimus (Toriselt; Wyeth
Pharmaceuticals, Philadelphia, PA, USA) alone, followed by
temsirolimus in combination with ketoconazole after a 14-day
washout period. On study day 1 of the first period, subjects
received 25mg i.v. diphenhydramine, followed 30min later by
5mg i.v. temsirolimus over 30min. Subjects remained in the
clinical unit until the 72-h blood collection (study day 4) and
returned for subsequent blood draws at designated time points
over the next 4 days (study days 5–8). Study days 9 through 13
were part of the washout period. During the second period,
subjects returned to the clinical unit on study day 14. On study day
15, they received 400mg oral ketoconazole, followed 90min later
by a 25-mg i.v. dose of diphenhydramine. Thirty minutes later,
subjects were administered a 30-min i.v. infusion of 5mg
temsirolimus. Subjects remained in the clinical unit until the 72-
h blood draw (study day 18) and returned for all subsequent blood
draws. They continued to take 400mg ketoconazole orally each day
through study day 21. Subjects fasted for 10h before receiving
temsirolimus and for 4h afterward.
Blood samples were collected predose, immediately before the
end of the infusion (0.5h), and at 1, 3, 8, 24, 48, 72, 96, 120, 144,
and 168h after administration of temsirolimus on study days 1 and
15. Samples were collected in evacuated tubes containing
ethylenediaminetetraacetic acid (EDTA) and gently mixed, then
stored upright at  701C until shipment. Samples were shipped on
ice to Taylor Technology (Princeton, NJ, USA) for measurement of
temsirolimus and sirolimus concentrations.
Bioanalytic assays
The concentrations of temsirolimus and sirolimus in blood were
measured simultaneously using validated liquid chromatography/
tandem mass spectrometry combination procedures with deuter-
ated internal standard (Punt et al, 2003). Analytes and internal
standard were extracted from a 1-ml sample of EDTA-treated
whole blood by liquid–liquid extraction with 1-chlorobutane and
separated with a YMC PDS AQ HPLC column (Waters, Milford,
MA, USA). Analytes were detected by tandem mass spectrometry
using atmospheric pressure chemical ionisation. The concentra-
tion of analytes was determined with calibration standards using
linear least squares regression.
The bioanalytic method for temsirolimus was validated through
the quantitation range of 0.25–100ngml
 1 and exhibited interday
and intraday variabilities, expressed as CV of o5% and biases of
o9.4% (Punt et al, 2003). The bioanalytic method for sirolimus
was validated through the quantitation range of 0.1–100ngml
 1
and exhibited interday and intraday variabilities of o12.7% and
biases of o11.3% (Punt et al, 2003). No interferences were
observed in blank blood or in blood spiked with internal standard.
Temsirolimus and sirolimus are stable in whole blood when stored
at  701C (Punt et al, 2003).
Pharmacokinetics
Pharmacokinetic parameters for temsirolimus were analysed for
each subject for each study period using non-compartmental
methods (Jusko, 1992). Scheduled times were used for all
calculations. The Cmax and the time to reach Cmax (Tmax) were
determined visually from the concentration–time curves. The
terminal elimination rate constant, lz, was estimated by log-linear
regression of the terminal portion of the whole blood concentra-
tion–time curves. The terminal elimination half-life (T1/2) was
calculated as 0.693/lz. The area under the concentration–time
curve (AUCT) was calculated using the trapezoidal rule for the
ascending portion of the curve, and the log-trapezoidal rule for
the descending portion of the curve. Total AUC was estimated
using the following equation: AUC¼AUCTþCT/lz, wherein CT is
the last observed blood concentration at time T. The AUCratio is the
ratio of sirolimus AUC to temsirolimus AUC (AUCsirolimus/
AUCtemsirolimus). Clearance (CL) is the volume of plasma cleared
of the drug per unit time (dose/AUC). Apparent clearance was
corrected for the fraction of the dose that was metabolised (CL/fm).
The apparent volume of distribution during the terminal phase
(Vz) was calculated by (CL/fm)/lz. The calculation of the steady-
state volume of distribution (Vdss) incorporated dissociation and
association rates of protein and tissue binding. Vdss was defined as
(dose/AUC)MRTu, where MRTu is the mean residence time of the
unbound drug in the plasma (Berezhkovskiy, 2004).
Statistics
The blood concentrations and PK parameters for temsirolimus and
sirolimus from both treatment periods were compared using a
one-factor analysis of variance (ANOVA) with treatment as a fixed
effect and subject as a random effect, using the WinNonlin
Enterprise application version 4.1 Linear Mixed Effects Wizard
(Pharsight Corp., Mountain View, CA, USA). The geometric mean
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srelative bioavailability of Cmax, AUC, and AUCT and the 90%
confidence limits were calculated using ANOVA to determine the
magnitude of the effect of ketoconazole. Vital signs, ECG intervals,
and laboratory parameters were screened for prespecified,
potentially clinically important criteria.
RESULTS
Study population
Seventeen subjects were enrolled in the study, and all but one were
men and most were white subjects (Table 1). During the study, 17
subjects received temsirolimus during period 1, whereas 14
subjects received temsirolimus with ketoconazole during period
2. Five subjects did not complete the study. During period 1, one
subject received only a partial dose of temsirolimus and withdrew
from the study after experiencing a local reaction to the i.v.
infusion, for which an ice pack was applied and the infiltration was
considered resolved. One other patient withdrew consent. During
period 2, one patient failed to return and two other patients
withdrew consent following period 2 treatment. Available data
from 16 subjects were included in the PK analyses, and all 17
subjects were included in the safety analyses.
Pharmacokinetics
The temsirolimus PK profile was evaluable for 16 subjects in
period 1 and for 14 subjects in period 2. Exposures to temsirolimus
and sirolimus were associated with a modest degree of intersubject
variability, with a CV for Cmax and AUC of o16% for temsirolimus
and o33% for sirolimus.
Mean concentration–time curves for temsirolimus in blood
were nearly comparable following treatment with ketoconazole in
combination with temsirolimus compared with temsirolimus alone
(Figure 1A). In contrast, the mean concentration of sirolimus over
time was greater in subjects receiving ketoconazole in combination
with temsirolimus than that in subjects receiving temsirolimus
alone (Figure 1B). Time to maximal concentration consistently
occurred at the end of infusion (0.5h) for temsirolimus and at 3h
for sirolimus, irrespective of treatment.
No substantial differences in mean Cmax and AUC for
temsirolimus were observed in subjects receiving temsirolimus
alone or in combination with ketoconazole (Table 2). Mean
volume of distribution of temsirolimus at steady state was 87 and
92 l without or with ketoconazole coadministration, respectively.
Mean clearance of temsirolimus decreased from 5.72 to 5.14lh
 1
(approximately 10%), but this decrease was not manifested as
changes in mean Cmax and AUC.
In contrast, for sirolimus, the change in mean apparent
metabolic clearance (CL/fm) was more substantial, decreasing
3.2-fold with ketoconazole treatment and resulting in an increase
in mean half-life from 75 to 113h. Carryover of sirolimus from
treatment period 1 to 2 was minimal, contributing 1.9% to the
mean total AUC calculated for this treatment period (range
1.1–3.7%). Ketoconazole increased sirolimus mean Cmax by 2.2-
fold and AUC by 3.2-fold compared with temsirolimus alone.
For temsirolimus, the least squares geometric mean ratios (90%
confidence intervals (CIs)) relative to the reference of a single dose
of 5-mg i.v. temsirolimus alone for Cmax, AUCT, and AUC were
94% (88%, 100%), 109% (103%, 116%), and 110% (105%, 115%),
respectively. For sirolimus, the least squares geometric mean ratios
(90% CIs) for Cmax, AUCT, and AUC were 224% (198%, 253%),
252% (232%, 272%), and 310% (277%, 345%), respectively
(Figure 2).
Safety
Adverse events, defined as those occurring or worsening after
receiving study medications, occurred in 71 and 57% of subjects
receiving temsirolimus and the combination of temsirolimus and
ketoconazole, respectively (Table 3). The most frequently reported
adverse events were headache, neutropaenia, pain, and insomnia.
No clinically important trends in laboratory results, vital signs, or
ECG intervals occurred between treatment groups. In fact, toxicity
profiles were comparable between the temsirolimus plus ketoco-
nazole and temsirolimus alone arms. No deaths or serious adverse
events were reported.
Table 1 Subject demographics and characteristics
Characteristic Total (n¼17)
Mean age (years) 33.7±8.9
Gender (n (%))
Women 1 (5.9)
Men 16 (94.1)
Height (cm) 175.9±5.9
Weight (kg) 79.8±10.8
Body mass index (kgm
 2) 25.8±3.1
Ethnicity (n (%))
Black or African American 6 (35.3)
Other: multiracial 1 (5.9)
White 10 (58.8)
0
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Temsirolimus alone
72 96 120 144 168
02 4 4 8
Temsirolimus+ketoconazole
Time (h)
Temsirolimus alone
72 96 120 144 168
100
10
1
0.1
Figure 1 Mean concentration vs time profile of temsirolimus (A) and
sirolimus (B) in whole blood following a single 5-mg i.v. dose of
temsirolimus alone or with multiple doses of ketoconazole.
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sDISCUSSION
Temsirolimus is a novel targeted therapy for the treatment of
patients with RCC and is currently in clinical studies for treatment
of various haematologic and solid malignancies. Patients with
advanced cancers often receive concomitant therapies to manage
disease symptoms and the side effects associated with anticancer
agents. It is therefore important to characterise the potential for
PK drug interactions in patients receiving i.v. temsirolimus and to
provide guidance on dose modifications, when appropriate.
We report that coadministration of ketoconazole, a strong
CYP3A4 inhibitor, with 5mg i.v. temsirolimus in healthy subjects
had no effect on temsirolimus Cmax or AUC. The 90% CIs for the
least squares geometric mean ratios of Cmax, AUCT, and AUC for
temsirolimus were within the 80–125% range, indicating no
clinically significant PK drug interaction. However, for the
metabolite sirolimus, 90% CIs for the least squares geometric
mean ratios of Cmax, AUCT, and AUC were greater than 200%,
indicating a clinically significant PK drug interaction. These
increases in sirolimus Cmax and AUC were accompanied by a 69%
reduction in sirolimus apparent clearance.
The clinical relevance of increased exposure to sirolimus PK for
patients with cancer receiving i.v. temsirolimus pertains to the
Table 2 Mean pharmacokinetic parameters of temsirolimus and sirolimus in whole blood
Temsirolimus, mean (CV) Sirolimus, mean (CV)
Pharmacokinetic
parameter
Temsirolimus
(5mg)
Temsirolimus (5mg)+
ketoconazole (400mg)
Temsirolimus
(5mg)
Temsirolimus (5mg)+
ketoconazole (400mg)
Cmax (ngml
 1) 278.3 (5.8%) 262.6 (15.5%) 13.3 (27.4%) 29.0 (13.6%)
Tmax (h) 0.5 (0) 0.5 (0) 3.3 (37.7%) 3.0 (0)
T1/2 (h) 22.3 (19.6%) 23.7 (17.0%) 74.8 (10.8%) 112.8 (18.1%)
AUCT (hngml
 1) 873.4 (11.9%) 969.1 (15.0%) 918.3 (28.3%) 2410.7 (22.0%)
AUC (hngml
 1) 885.5 (11.7%) 991.6 (14.5%) 1204.7 (30.2%) 3888.9 (29.2%)
CL
a (lh
 1) 5.7 (11.0%) 5.1 (13.8%) 4.5 (28.6%) 1.4 (32.7%)
Vz
b (l) 182.0 (17.1%) 173.6 (16.4%) 479.7 (27.5%) 220.4 (24.5%)
Vss
c (l) 86.8 (14.6%) 91.5 (17.5%) 493.6 (25.4%) 227.1 (22.0%)
AUCratio 1.35 (23.9%) 3.94 (28.0%)
AUCsum (hngml
 1) 2090 (21.0%) 4881 (25.0%)
AUC¼area under the concentration curve; AUCsum¼sum of temsirolimus plus sirolimus AUC; AUCT¼area under the concentration–time curve; CL¼clearance;
Cmax¼maximum concentration; T1/2¼half-life; Tmax¼time to reach Cmax; Vz¼apparent volume of distribution during the terminal phase; Vss¼steady-state volume of
distribution.
aFor sirolimus¼CL/fm (lh
 1).
bFor sirolimus¼Vz/fm (l).
cFor sirolimus¼Vss/fm (l).
Index 125%
Index 80%
Parameter
TEMSR ln(C max )
TEMSR ln(AUC
T ) 
TEMSR ln(AUC)
SIR ln(C
max )
SIR ln(AUC
T ) 
SIR ln(AUC)
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Figure 2 Least squares geometric mean ratios of temsirolimus (TEMSR)
and sirolimus (SIR) Cmax, AUCT, and AUC following a single 5-mg i.v. dose
of temsirolimus alone or with multiple doses of ketoconazole, in healthy
subjects.
Table 3 Treatment-emergent adverse events
Body system
adverse event,
n (%)
Temsirolimus
(5mg) (n¼17)
Temsirolimus
(5mg)+ketoconazole
(400mg) (n¼14)
Any adverse event 12 (71) 8 (57)
Body as a whole
Back pain 1 (5.9) 0
Chills 0 1 (7.1)
Headache 4 (23.5) 2 (21.4)
Neck pain 1 (5.9) 0
Pain 2 (11.8) 0
Cardiovascular system
Syncope 1 (5.9) 0
Tachycardia sinus 1 (5.9) 0
Vascular headache 0 1 (7.1)
Digestive system
Aphthous stomatitis 0 1 (7.1)
Dry mouth 1 (5.9) 0
Dyspepsia 0 1 (7.1)
Mouth pain 1 (5.9) 0
Nausea 0 1 (7.1)
Haemic and lymphatic system
Granulocytosis 1 (5.9) 0
Neutropaenia 3 (17.6) 1 (7.1)
Nervous system
Hostility 0 1 (7.1)
Insomnia 1 (5.9) 0
Nervousness 0 1 (7.1)
Tremor 0 1 (7.1)
Twitching 0 1 (7.1)
Respiratory system
Epitaxis 0 1 (7.1)
Rhinitis 1 (5.9) 0
Skin and appendages
Herpes simplex 1 (5.9) 0
Rash 1 (5.9) 0
Special senses
Visual field defect 0 1 (7.1)
Adverse event associated with miscellaneous factors
Local reaction to procedure 1 (5.9) 0
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spotential for increased incidence or severity of toxicities rather
than efficacy concerns. With 5mg i.v. temsirolimus, ketoconazole
increased the sirolimus/temsirolimus AUCratio 2.9-fold (from 1.35
to 3.94). Despite greater exposure to sirolimus, increases in toxicity
were not evident in these healthy subjects. The most common
adverse events were headache, neutropaenia, pain, and insomnia.
Notwithstanding the lower 5mg dose administered in this study,
the types of adverse events observed were not dissimilar to those
seen in studies of temsirolimus in patients with cancer, although a
greater percentage of cancer patients had thrombocytopaenia,
rash, and mucositis (Atkins et al, 2004; Hidalgo et al, 2006) than
did the healthy subjects in this study. Previous studies have
suggested that the incidence and severity of some adverse events
are proportional to the exposure to temsirolimus (Boni et al, 2005;
Chang et al, 2005). In a population PK safety analysis of patients
receiving 25, 75, or 250mg of temsirolimus weekly, clinically
interesting associations between AUCsum and adverse event
severity were observed for thrombocytopaenia (P¼0.007), pruritus
(P¼0.011), and hypertriglyceridaemia (P¼0.040) (Boni et al,
2005). Based on both logistic regression analyses, where predicted
drug concentrations can estimate the probability of adverse events,
and the tolerability of temsirolimus over a wide dose range, the
likelihood of severe toxicity occurring from this type of drug
interaction is thought to be low with the 25-mg dose. However, if
strong CYP3A4 inhibitors need to be used, a temsirolimus dose
reduction to 12.5mg should be considered.
Sirolimus appears to be more sensitive than temsirolimus to
both strong CYP3A4 inhibitors and strong CYP3A4-inducing
agents. Rifampin, a potent inducer of CYP3A4, had no effect on
temsirolimus AUC but reduced sirolimus AUC by 56% in healthy
adults (Boni et al, 2007). A study in cancer patients showed 36 and
67% reductions in Cmax for temsirolimus and sirolimus, respec-
tively, with concomitant enzyme-inducing anticonvulsant agents
(such as carbamazepine, phenytoin, and clonazepam), as well as a
45% reduction in sirolimus AUC (Boni et al, 2007).
This is the first report of the effects of concomitant CYP3A4
inhibitors on the PK of temsirolimus. However, the effects of
CYP3A4 inhibitors, including various macrolide antibiotics and
azole antifungal medications, on the metabolism of oral sirolimus
(rapamycin; Rapamune
s, Wyeth Pharmaceuticals) have been
previously described by Zimmerman (2004). Coadministration of
ketoconazole with i.v. temsirolimus leads to increased blood levels
of the sirolimus metabolite (3.1-fold); however, the magnitude of
this increase was more profound with oral sirolimus (almost 10-
fold) (Zimmerman, 2004). It is likely that ketoconazole-mediated
inhibition of CYP3A4 metabolism in the gastrointestinal epithe-
lium plays a significant role in enhancing first-pass absorption
following oral administration of CYP3A4 substrates like sirolimus.
Intravenous administration, as is employed with temsirolimus,
largely avoids first-pass presentation of drug to the gut so
that this mechanism has less of a bearing on drug interaction
potential.
Temsirolimus and sirolimus are both substrates of CYP3A4, but
neither is an inhibitor or an inducer of CYP3A4. Thus, the effect of
i.v. temsirolimus administration on the metabolism of other
CYP3A4 substrates should be minimal or negligible. These include
HMG-CoA reductase inhibitors and glucose-lowering agents
(commonly used to treat hyperlipidaemia and hyperglycaemia,
respectively, that may be related to temsirolimus), benzodiaze-
pines (commonly used in cancer patients for anxiety), and calcium
channel blockers (commonly used antihypertensives). Although
antifungal agents that are strong inhibitors of CYP3A4 (e.g.,
ketoconazole and itraconazole) should be avoided in patients
receiving temsirolimus, moderate CYP3A4 inhibitors (e.g., fluco-
nazole and voriconazole) may not have as much interaction
potential. For example, in RCC patients treated with 25mg i.v.
temsirolimus, fluconazole (commonly used for treatment of
chemotherapy-induced mucositis) may be a reasonable manage-
ment approach for temsirolimus-related mucositis. Nevertheless,
CYP3A4 inhibitors should not be given concomitantly with higher
temsirolimus doses, such as those being investigated in clinical
trials (e.g., 175mg for mantle cell lymphoma).
In conclusion, coadministration of ketoconazole with i.v.
temsirolimus had no effect on temsirolimus Cmax or AUC;
however, a strong PK interaction leading to increased exposure
of the primary metabolite sirolimus (Cmax, 2.2-fold; AUC, 3.1-fold)
was observed. Based on these results, it is recommended that
concomitant use of strong CYP3A4 inhibitors should be avoided
(e.g., ketoconazole, itraconazole, clarithromycin, atazanavir,
indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithro-
mycin, and voriconazole) in cancer patients receiving 25mg i.v.
temsirolimus once weekly. Grapefruit juice may also increase
plasma concentration of sirolimus. If a concomitant strong
CYP3A4 inhibitor is necessary, a temsirolimus dose reduction to
12.5mg weekly should be considered. If the strong CYP3A4
inhibitor is discontinued, a washout period of approximately 1
week should be allowed before the temsirolimus dose is adjusted
back to the dose used before initiation of the strong CYP3A4
inhibitor.
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